<DOC>
	<DOCNO>NCT02697370</DOCNO>
	<brief_summary>Patients severe Haemophilia A need prophylactic factor VIII reduce risk joint soft tissue bleeds prevent reduce joint damage . It common practice give enough factor VIII maintain trough level 1 % normal support retrospective study . The amount factor VIII require maintain trough level varies markedly patient factor VIII half live different . This study assess role regular pharmacokinetic ( PK ) monitoring dose adjust factor VIII establish whether cost effective way give treatment whether feasible routine clinical practice . Patients treat 6 month standard factor VIII regimen follow establish bleed frequency . They receive pharmacokinetic adjusted factor VIII maintain trough 1.5 % year bleed rate compare standard treatment . If increase break bleeds factor VIII increase maintain trough 3 % .</brief_summary>
	<brief_title>Efficacy Cost Effectiveness Pharmacokinetic Dosing Haemophilia A</brief_title>
	<detailed_description>Study procedure Recruitment Consent Patients severe Haemophilia A take regular prophylactic regimen infusion factor VIII least 3 time week target joint eligible . Initial approach make Principal Investigator patient next scheduled review appointment . Phase 1 : Study enrolment Participants allocate unique patient number upon enrolment study . The follow record study enrolment : - Date birth - Height weight - Baseline factor VIII base historical data patient record - History factor VIII inhibitor - Information number site haemarthroses soft tissue bleeds total amount factor VIII use precede 12 month record , know - Quality life assessment Utility-EQ5D - Joint assessment Haemophilia Joint Health Score ( HJHS ) An abbreviate ( 3 sample ) pharmacokinetic study undertaken follow : There wash . The patient 's routine prophylactic infusion give morning exact time ( hour minute ) dose record . Since wash date , exact time dose previous 2 prophylactic dos ( i.e . 3 infusion total ) must accurately know . Blood sample take measure 1 . Factor VIII level 2 . Von Willebrand factor ( VWF ) antigen level 3 . Von Willebrand factor propeptide 4 . Von Willebrand factor : factor VIII binding 5 . Coagulation screen 6 . Inhibitor assay Nijmegen modification Bethesda assay &amp; ELISA ( first afternoon timepoint ) 7 . CRP ( first afternoon time point ) Samples test collect afternoon , follow morning follow afternoon . The sample take convenient time exact time ( hour minute ) must record . Factor VIII level measure . The patient 's weight ( kg ) , amount exact time last 3 factor VIII infusion , measure factor VIII level exact time sample take communicated centre Uppsala pharmacokinetic parameter establish use Bayesian procedure base population model . The follow establish recorded note already know 1 . Blood group 2 . Factor VIII mutation 3 . DNA test gene may affect factor VIII clearance e.g . lipoprotein receptor 4 . Factor VIII Von Willebrand factor genetic sequence Phase 2 : Standard treatment 6 month The patient remain routine prophylactic regimen determine clinician period 6 month . The patient 's current factor VIII product use factor VIII product change throughout study . Patients instruct give prophylactic infusion morning ( define midday ) . The following procedure undertaken : Patients keep diary : All factor VIII infusion . Information collect dose factor VIII , time ( hour minute ) infusion reason infusion ( prophylaxis treatment bleed ) . b Bleeding event . Information collect type bleed ( haemarthrosis soft tissue ) , site ( identify specific joint position ) , cause ( atraumatic traumatic precipitate event ) , symptoms sign swell , pain loss function time . Every 2 week first 2 month subsequently monthly nurse doctor make contact telephone , email text confirm diary complete . At 3 month doctor review patient diary make appropriate change treatment . Patients open access contact attend Haemophilia Centre currently case . The clinician make appropriate change treatment . Phase 3 : Pharmacokinetic tailor treatment At end phase 2 , i.e . 6 month start study patient attend haemophilia centre : - Review bleed chart diary treatment - QOL assessment ( Utility-EQ5D ) - Joint assessment ( HJHS ) - An abbreviated ( 3 sample ) pharmacokinetic study undertaken follow : As wash . The patient 's routine prophylactic infusion give morning exact time dose record . Also date , exact time dose previous 2 prophylactic dos ( i.e . 3 infusion total ) must accurately know record . Blood sample collect measure parameter Phase 1 The centre Uppsala use pharmacokinetic data calculate dose factor VIII ( infused alternate day ) require maintain predict factor VIII ≥1.5 IU/dL time , inform patient 's centre dose prescribe ( rounded nearest full 250 IU vial ) . This regimen prescribe 12 month i.e . month 7-18 study . The patient 's current factor VIII product use . Patients instruct give prophylactic infusion morning ( define midday ) . The patient follow procedure keep diary Phase 1 . At 3 , 6 9 month ( +/- 2 week ) start pharmacokinetic tailor treatment phase ( i.e . end 9 , 12 15 month ( +/- 2 week ) start study ) , doctor review patient diary make appropriate change treatment accord Phase 3 dose escalation protocol . At visit participant weight factor VIII level measure As wash . The patient 's routine prophylactic infusion give morning exact time dose record . The date , exact time dose previous 2 prophylactic dos must also accurately know record . Blood sample collect afternoon , follow morning follow afternoon parameter measure Phase 1 . The Uppsala centre calculate pharmacokinetic parameter . Based result dose required patient review recommend appropriate dose maintain trough level ≥ 1.5 IU/dL . Dose escalation Phase 2 If participant experience one clinically significant bleed 4 month period phase 2 ( clinician routine prescribing ) treatment adjust clinician accord clinician 's routine practice . This could mean prophylactic dose change . Phase 3 If participant experience one clinically significant bleed 4 month period phase 3 ( pharmacokinetic tailor dosing ) dose escalation occur . The participant prophylaxis dose increase sustain trough factor VIII level 3 IU/dL i.e . prophylactic dose double . If participant one clinically significant bleed subsequent 4 month period withdrawn study return routine care . This mean 4 clinically significant bleeds , per participant , permit phase 3 ( 1 year ) study . This figure base find 5 % patient full dose standard prophylaxis 3 bleeds per year median number bleeds prospective prophylaxis study adult patient 0 3 per year . Study end After 18 month patient undergo : - Weight measurement - Diary review bleeds , treatment adverse event - Quality life assessment Utility-EQ5D - Joint assessment HJHS - Blood take parameter Phase 1 The patient exit study . Adverse Events A clinical review hold clinically significant bleed phase 3 study . If participant experience 4 bleeds phase 3 study , class adverse event participant withdrawn study . If 5 participant 1 spontaneous clinically significant bleed 4 month period dose escalation 3 % , study review IDMC confirm participant revert back standard care study terminate . Pharmacokinetic analysis dose recommendation Calculation pharmacokinetic parameter dose factor VIII prophylactic phase 3 perform Department Pharmaceutical Biosciences , Uppsala University , supervision Professor Bjorkman use NonmemR software . The factor VIII level , time dose factor VIII infusion patient ' weight send Uppsala . No information send . The dose recommendation send treat centre secure email within 7 day . The local centre use information available Uppsala TCIworksR software calculate patient ' pharmacokinetics dose recommendation . The dose recommendation Uppsala use local recommendation different . Method measurement patient pharmacokinetics The study patient ' pharmacokinetic parameter estimate Bayesian procedure base population model , accord method already use e.g . aminoglycoside antibiotic , digoxin immunomodulating drug . Pharmacokinetic parameter estimate obtain 6 month result update new data obtain 9 , 12 , 15 18 month . A complete population pharmacokinetic analysis perform collection data aim investigate : 1 . Intra-individual ( inter-occasion ) variance pharmacokinetics relationship inter-individual variance . 2 . The relationship pharmacokinetic variable patient characteristic ( determine study occasion ) , particular VWF : Ag level , VWF : factor VIII binding , VWF propeptide , blood group , inflammation ( CRP ) , inhibitor titre factor VIII mutation . Analysis First ; primary secondary endpoint compare phase I II i.e . number clinically significant bleeds , total bleeds , clot factor consumption/kg , quality life , joint status . These comparison perform use pair T-tests non parametric test . Second ; performance pharmacokinetic calculation method assess : predict FVIII level compare measure FVIII level , inter- well inter patient variability PK parameter assess . Third ; determinant bleed rate address use multivariate regression negative binomial model joint bleeds well total bleeds outcome . Using approach , independent effect calculate weekly time 1 % , baseline arthropathy , physical activity assess . Fourth ; association patient characteristic ( age , weight , BMI , blood group , VWF level , factor VIII mutation , VWF : FVIII binding , VWF polymorphism , current past history factor VIII inhibitor inflammation ) PK parameter ( AUC half life ) assess use multivariate regression technique . Finally , patient characteristic associate treatment failure ( e.g . low predict factor VIII level , high activity , non-reproducible pharmacokinetic result lack adherence ) assess , use descriptive statistic multivariate logistic regression possible . The study deem positive outcome : 1 . Patients treat factor VIII dose calculate individual pharmacokinetics 12 month least 80 % case . 2 . The median increase clinically significant bleeds pharmacokinetic dose arm compare routine practice less 2 80 % patient 3 . There statistically significant reduction average factor VIII usage pharmacokinetic dose period compare clinician dosed period .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe haemophilia A ( baseline factor VIII &lt; 1IU/dL ) Age 18 year Patients take regular prophylactic regimen ( define regular factor VIII infusion , least 3 time week , aim minimising haemarthroses clinically significant bleeds ) . Low titre inhibitor , past history inhibitor , abnormal liver function , drug interfere haemostasis low CD4 count allow . Presence target joint prophylaxis ( defined 3 bleeds one joint , 6 month period , last year ) . The occurrence 3 haemarthroses last year require 2 infusion resolve</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Haemophilia A prophylaxis pharmacokinetic dosing</keyword>
</DOC>